| |
| Device | Oncomine Dx Target Test |
| Generic Name | Next generation sequencing oncology panel, somatic or germline variant detection system |
| Applicant | Life Technologies Corporation 5781 Van Allen Way Carlsbad, CA 92008 |
| PMA Number | P160045 |
| Supplement Number | S048 |
| Date Received | 06/04/2024 |
| Decision Date | 07/02/2024 |
| Product Code |
PQP |
| Advisory Committee |
Pathology |
| Supplement Type | Special (Immediate Track) |
| Supplement Reason | Labeling Change - Indications/instructions/shelf life/tradename |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement Approved for the removal of the companion diagnostic (CDx) indication for EXKIVITY (mobocertinib) for patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertions from the Oncomine Dx Target Test label. |